The purpose of the trial is to find out whether adding orelabrutinib to the usual regimen can keep the disease from getting worse for a longer period of time. After a screening visit, participants are randomly assigned to one of the two groups, and neither the participants nor the doctors know which group they are in. Treatment is given in repeated cycles over several months, with regular check‑ups that include blood tests, heart checks, and questionnaires about quality of life. The study follows participants for several years to see how long they stay free of disease progression and to monitor safety.

In this study, participants are assigned to one of the treatment groups by chance. One group receives tirabrutinib alone, and the other group receives rituximab plus temozolomide. Treatment is given over a period of time with regular study visits, and health is checked throughout the study to see how the disease responds and how long the disease stays under control. The study also looks at overall survival, which means how long people live after joining the study, and at changes in steroid medicine use.

This is a Phase 3 study, which means the treatment is being compared in a larger group of people to help show how well it works and how safe it is. It is a randomized study, so the treatment group is chosen by chance, and it is open-label, which means both the study team and the participants know which treatment is being given.

Participants in the study will receive either the HLX10 treatment or a placebo, alongside the standard chemotherapy and radiotherapy. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the HLX10 or the placebo. This helps ensure that the results are unbiased. The study will take place over a period of time, with regular monitoring to assess the treatment’s impact on the cancer and any side effects experienced by the participants.

The main goal is to see if the combination of HLX10 with chemotherapy and radiotherapy can improve overall survival rates for patients with LS-SCLC. Secondary goals include measuring progression-free survival, which is the length of time during and after treatment that a patient lives with the disease without it getting worse, and the objective response rate, which is the proportion of patients whose cancer shrinks or disappears after treatment. The study will also monitor the quality of life of participants and any adverse events that occur during the trial.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The study is testing whether adding the experimental oral drug pelabresib (code name DAK539) to the approved oral medication ruxolitinib improves reduction of spleen size and relief of symptoms compared with taking ruxolitinib together with a placebo. The purpose of the study is to determine if the combination therapy provides a greater benefit than the standard treatment alone.

Participants will take the study tablets each day for several months. Throughout the trial they will undergo imaging tests, such as MRI or CT scan, to measure the size of the spleen, and they will complete simple questionnaires about how they feel. Regular health checks will be performed to monitor safety, and the study will continue for about a year to observe how the treatment works over time.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The purpose of the study is to see whether olomorasib, when added to standard immunotherapy, works better and is safe for people with this type of lung cancer. The study is done in different parts. After treatment begins, participants are followed over time while taking the study medicine or placebo together with the immunotherapy medicine, and health checks are done throughout the study to watch for side effects and any changes in the cancer.

In the study, treatment is given over a long period of time, and people are followed while they receive one of the study medicines. The study looks at how often a blood clot in a vein happens after treatment starts. The medicines being studied are baricitinib, adalimumab, and etanercept.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The study medication tezepelumab is given as a subcutaneous injection using a pre-filled syringe. Some participants will receive tezepelumab, while others will receive a placebo. Neither the participants nor their doctors will know which treatment is being given during the study.

The treatment period will last for 76 weeks, during which participants will receive regular injections of either tezepelumab or placebo. Throughout the study, doctors will monitor participants’ breathing ability, symptoms, and how often they experience COPD flare-ups. The study will also track any changes in participants’ quality of life and their ability to perform daily activities.

The purpose of the study is to assess whether RO7790121 can help patients achieve clinical remission, which means a significant reduction in disease activity, and an endoscopic response, which refers to visible improvements in the digestive tract as seen through an endoscope. Participants in the study will receive either the treatment or a placebo, and their progress will be monitored over time to see how well the treatment works in reducing symptoms and improving their condition.

Throughout the study, researchers will track various outcomes, such as the overall change in symptoms, the severity of symptoms, and the general well-being of participants. They will also monitor any adverse events, which are unwanted effects that might occur during the trial. The study aims to provide valuable information on the potential benefits and risks of using RO7790121 for treating Crohn’s Disease, helping to improve future treatment options for those affected by this condition.

The purpose of the study is to assess how effective and safe sonelokimab is for adults with moderate to severe hidradenitis suppurativa. Participants in the study will receive either sonelokimab or a placebo over a period of 16 weeks. During this time, researchers will monitor the participants to see if there is a 75% improvement in their condition, as measured by a specific score called the Hidradenitis Suppurativa Clinical Response (HiSCR) score. The study will also track any side effects or adverse events that occur during the treatment period.

Throughout the study, participants will undergo regular check-ups, including physical examinations and laboratory tests, to ensure their safety and to gather data on the treatment’s effects. The study aims to provide valuable information on whether sonelokimab can be a beneficial treatment option for those suffering from hidradenitis suppurativa.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

During the study, participants will take these medications as part of a treatment plan. The process involves monitoring the disease to see how the body responds to the combined medicines. The study will follow the participants over time to see how long the treatment keeps the cancer under control and to ensure the medications are being used safely.

Participants in the study will be assigned to receive either muvalaplin, which is taken as an oral tablet, or a placebo. This is a randomized study, meaning the treatment assigned is determined by chance, and it is double-blind, so neither the participants nor the researchers know which treatment is being given during the trial. The study will monitor how the medication affects the risk of experiencing major heart events over time.

The purpose of the study is to evaluate how well these treatments work and how safe they are for patients. Participants will receive either Zilovertamab Vedotin alone or together with Nemtabrutinib. Zilovertamab Vedotin is given as an injection into a vein, while Nemtabrutinib is taken as a tablet by mouth. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients.

The study will take place over several weeks, during which participants will be closely monitored by healthcare professionals. They will undergo regular check-ups and tests to assess their response to the treatment and to ensure their safety. The study aims to provide valuable information that could lead to better treatment options for people with these types of blood cancers.

The purpose of this study is to find out if treatment with linvoseltamab alone or linvoseltamab combined with carfilzomib works better than standard treatments for multiple myeloma that has returned or stopped responding to previous therapy. The study will measure how many patients have no signs of cancer cells remaining in their body after twelve months of treatment and how long patients live without their cancer getting worse. The study will also look at how safe these treatments are and what side effects patients may experience.

The study has two parts. In the first part, a small number of patients will receive linvoseltamab or linvoseltamab with carfilzomib to check that the dosing schedule is safe. In the second part, a larger group of patients will be randomly assigned to receive either linvoseltamab alone, linvoseltamab with carfilzomib, or standard treatment combinations. Patients will receive their assigned treatment in cycles lasting twenty-eight days. During the study, patients will have regular check-ups, blood tests, and other examinations to see how well the treatment is working and to monitor for any side effects. The study will also ask patients questions about their quality of life and how they are feeling.

The purpose of this study is to find out if adding Revumenib to intensive chemotherapy helps people with this type of leukemia live longer without their disease getting worse compared to chemotherapy alone, and to see if this combination helps more people achieve complete remission with no detectable signs of cancer cells remaining in their bone marrow. During the study, participants will receive their assigned treatment and will be monitored regularly to check how well the treatment is working and to watch for any side effects. The study will track various outcomes including how long participants live, how long they remain in remission, and how many participants achieve complete remission with no measurable remaining disease.

The study will also carefully monitor the safety of the treatment by recording any unwanted effects that occur, checking blood test results regularly, and performing heart function tests and other examinations. Doctors will measure treatment success by looking at whether the cancer goes away completely, whether cancer cells can still be detected in the bone marrow or blood using special tests, and how long participants remain free of cancer. The study is expected to continue for several years to gather enough information about the long-term effects of this treatment combination.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of this study is to compare how well the combination of belzutifan and zanzalintinib works against cabozantinib in treating advanced kidney cancer. The study will look at how long people live without their cancer getting worse and how long they live overall. The study will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long that response lasts.

During the study, people will be randomly assigned to receive either the combination treatment or cabozantinib alone. The study will track any unwanted effects that occur and whether people need to stop treatment because of these effects. The study will also measure quality of life and how well people are able to carry out daily activities using questionnaires that ask about physical health, ability to perform usual activities, and symptoms related to kidney cancer. The study will continue to follow people over time to gather information about how the treatments affect their cancer and overall health.

The purpose of this study is to evaluate the long-term safety and how well mezagitamab works in adults who have already participated in previous studies with this medicine and completed those studies. The study will look at whether the treatment causes any unwanted effects over a longer period of time and whether it continues to help maintain platelet counts at safe levels. The study will also examine how long the positive effects on platelet counts last, whether people need fewer other medicines for their condition, and whether they need less emergency treatment for low platelet counts.

During the study, participants will receive mezagitamab through subcutaneous injection, which means the medicine is injected into the tissue just under the skin. The treatment can continue for up to 104 weeks. Throughout the study, doctors will monitor participants for any side effects and measure how the body responds to the treatment by checking platelet counts and other blood tests. The study will also check how the medicine moves through the body and whether the body develops any reaction against the medicine over time.